Shares of Orexigen Therapeutics Inc. (Nasdaq: OREX) climbed again by gaining 84 cents to $5.76 after rival Arena Pharmaceuticals Inc.'s (Nasdaq: ARNA) weight loss treatment Lorcaserin was approved yesterday. Arena stock dropped $1.29 to $10.10 as investors locked in profits on the biopharmaceutical.
FinancialContent is the trusted provider of stock market information to the media industry.
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial